Fennec Pharmaceuticals Inc expected to post a loss of 9 cents a share - Earnings Preview

Fennec Pharmaceuticals

09/05/2025 15:58

Fennec Pharmaceuticals Inc FENC.OQ FENC.O is expected to show a fall in quarterly revenue when it reports  results on May 13 for the period ending March 31 2025

The Research Triangle Park North Carolina-based  company is expected to report a 67.8% decrease in revenue to $8.181 million from $25.38 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Fennec Pharmaceuticals Inc is for a loss of 9 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Fennec Pharmaceuticals Inc is $13.00​, above​ its last closing price of $6.21. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Dec. 31 2024
0.44
0.17
-0.06
Missed
-136.1
Sep. 30 2024
-0.14
-0.09
-0.21
Missed
-133.3
Jun. 30 2024
-0.11
-0.03
-0.20
Missed
-552.1​
Mar. 31 2024
0.30
0.26
0.47
Beat
79.4
​​Dec. 31 2023
-0.05
-0.02
-0.10
Missed
-410.2
Sep. 30 2023
-0.12
-0.12
-0.07
Beat
41.7​
Jun. 30 2023
-0.17
-0.16
-0.21
Missed
-34.2
Mar. 31 2023
-0.21
-0.21
-0.23
Missed
-9.6

This summary was machine generated May 9 at 14:58 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)